Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.53 |
| ▸ | CDK9 | P50750 | 3/20 | 0.53 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756696 | 0.90 | CSF1R (0.46) | CDK2CCNT1CCNE1CDK9CDK4 | |
| SCHEMBL13756837 | 0.87 | CDK2 (0.56) | CDK2CCNT1CCNE1CDK9CDK4 | |
| SCHEMBL13756768 | 0.86 | NUAK1 (0.44) | CDK2CCNT1CCNE1CDK9CDK4 | |
| SCHEMBL1655112 | 0.81 | RPS6KA3 (0.57) | CDK2CCNT1CCNE1CDK9CDK4 | |
| SCHEMBL13756838 | 0.80 | GRM5 (0.53) | CDK2CCNT1CCNE1CDK9NTRK1 | |
| SCHEMBL13756888 | 0.80 | CSF1R (0.43) | CDK4NTRK1EPHX2CSF1RFLT3 | |
| SCHEMBL13756767 | 0.78 | CDK2 (0.46) | CDK2CCNT1CCNE1CDK9CDK4 | |
| SCHEMBL13756769 | 0.78 | NUAK1 (0.54) | CDK2CDK4CCND1NUAK1CCNA2 | |
| SCHEMBL13756839 | 0.78 | JAK2 (0.55) | CDK2CCNT1CCNE1CDK9CDK4 | |
| SCHEMBL13756776 | 0.77 | PDGFRB (0.52) | CDK2CCNT1CCNE1CDK9NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CDK2 77/4885CCNT1 799/4885CCNE1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.